Michel Goldman

Laboratoire d'Immunologie Expérimentale, Hôpital Erasme, Belgium

Michel Goldman

Academic positions:
- Head of the Department of Immunology-Hematology-Transfusion, Hôpital Erasme, Université Libre de Bruxelles
- Director of the new Institute of Medical Immunology built at Charleroi-Gosselies (Belgium).

All industry positions (in last five years):
None declared

Research interests:
His major scientific achievements include pioneer clinical studies with biotechnology-derived products in kidney transplant recipients, identification of new mechanisms underlying rejection and tolerance to allografts, characterization of a key molecular defect in the neonatal system of human newborns, and discovery of a new immunosuppressive drug targeting calcium channels in T lymphocytes.

Current projects include;
- Immunobiology of the dentritic cells: To identify the factors controlling the various functions of the dendritic cells.
- Experimental transplantation: Development of strategies of induction of tolerance to the allogreffes.
- Immunity of the mucous membranes in the AIDS: Analyze by ELISPOT of the production of the cytokines by the intestinal lymphocytes at the patient infected by virus HIV.
- Biocompatibility of the membranes of dialysis: Study of the mechanisms of the inflammatory reactions induced by the membranes of dialysis.
- Cytokines in Immunopathologie human and experimental: Studies on the implications of the cytokines in the pathogenesis and the processing of human and experimental inflammatory diseases

Any other information:
Michel Goldman is the coordinator of an Integrated Project on Transplantation Tolerance ("RISET") recently launched by the European Commission. He is member of the Executive Committee of the "European Journal of Immunology" and serves in the editorial boards of "Transplantation" and "Clinical Experimental Immunology".

Michel Goldman received in 2000 the Joseph Maisin Prize, a major award for clinical sciences delivered by the Fonds National de la Recherche Scientifique (Belgium). He held the Spinoza chair at the University of Amsterdam in 2001 and was the President of the Sixth International Conference on New Trends in Clinical and Experimental Immunosuppression in Geneva in February 2002.

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Rheumatology & Clinical Immunology > Clinical Immunology (since 14 November 2005)

Links

http://www.ulb.ac.be/imi

All recent recommendations

• 6.0
  Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants.
  Recommended by Michel Goldman
  
• 6.0
  The NALP3 inflammasome is involved in the innate immune response to amyloid-beta.
  Recommended by Michel Goldman
  
• 6.4
  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
  Recommended by Myla Goldman, Michel Goldman
  
• 6.5
  Treatment of patients with the hypereosinophilic syndrome with mepolizumab.
  Recommended by Michel Goldman, Cem Akin with Anna Kovalszki, Lindy Fox
  
• 3.0
  Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy.
  Recommended by Michel Goldman
  
• 3.0
  Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation.
  Recommended by Michel Goldman
  
• 6.0
  A key role of leptin in the control of regulatory T cell proliferation.
  Recommended by Michel Goldman
  
• 3.0
  Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease.
  Recommended by Michel Goldman
  
• 6.6
  Restoring function in exhausted CD8 T cells during chronic viral infection.
  Recommended by Michel Goldman, Sibylle Schneider-Schaulies, Pierre Coulie
  
• 4.8
  Messenger RNA for FOXP3 in the urine of renal-allograft recipients.
  Recommended by Michel Goldman, Eva Guinan
  
• 3.0
  A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17.
  Recommended by Michel Goldman
  
• 9.0
  Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function.
  Recommended by Michel Goldman